The use of 2-deoxy-2-[18F] fluoro-D-glucose (FDG) and positron emission tomography/
computed tomography (PET/CT) is increasing rapidly – and the list of emerging and evolving applications is everexpanding
in a multitude of clinical settings. In this anniversary review celebrating four decades of FDG, we will outline
an overview of the present status of FDG imaging with emphasis on clinical implementation in the main indications of
FDG-PET/CT, i.e. neurology and psychiatry, oncology, cardiovascular diseases, and infectious and inflammatory diseases,
including some general considerations towards clinical benefit and potential future directions.
Keywords: FDG, PET, PET/CT, PET/MRI, cardiology, clinical drug development, infection, inflammation, pediatrics, neurology
psychiatry, oncology, radiation therapy planning.
Rights & PermissionsPrintExport